Akers Biosciences, Inc. US Patent - Heparin/PF4 Antibody Detection (9560S)
23 March 2016 - 6:00PM
UK Regulatory
TIDMAKR
RNS Number : 9560S
Akers Biosciences, Inc.
23 March 2016
Embargoed: 0700hrs 23 March 2016
Akers Biosciences, Inc.
US Patent Granted for Akers' Heparin/PF4 Antibody Detection
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces that the United States Patent and Trademark
Office has allowed a patent covering Akers Bio's proprietary
methods for detecting heparin/platelet factor 4 antibodies (the
"Patent").
Akers Bio's flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS
PF4 tests were designed to quickly determine if a patient being
treated with the blood thinner heparin may be developing
heparin-induced thrombocytopenia ("HIT"). This clinical syndrome
reverses the heparin's intended therapeutic effect and transforms
it into a clotting agent. Patients suffering HIT are at risk of
developing limb- and life-threatening complications, so the timely
test result provided by the Company's Heparin/PF4 devices is
paramount to effective and cost-efficient clinical decision
making.
Akers Bio's Heparin/PF4 devices determine if a patient may be
developing HIT by identifying the presence of heparin/platelet
factor 4 antibodies. The newly allowed Patent covers Akers Bio's
proprietary protein preparation which serves as the antigen and
biologically active component of the tests.
"Having developed the only FDA-cleared rapid manual assays for
determining if a patient may be developing HIT, it is essential to
ensure the Company has multi-faceted, robust patent protection that
further underpins their future value," said Raymond F. Akers, Jr.
PhD, Co-Founder and Executive Chairman. "This Patent is
particularly important because it protects the antigen that gives
our tests their superior accuracy. With published studies that
demonstrate that our tests never deliver a false positive result,
we believe them to be the most accurate available way to rule out
HIT," continued Dr. Akers.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9700
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXDAAFSKEFF
(END) Dow Jones Newswires
March 23, 2016 03:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024